SASB ESG DataTables 2023

At Genmab, we are committed to our business-driven CSR strategy as
we work together to build a sustainable organization that focuses on
our material environmental, social and governance (ESG) issues.
In line with the evolving reporting of sustainability, we continue toadapt and improve our metrics and disclosures. To this end, we haveidentified an initial set of performance indicators that will enable us tobetter manage and measure our impact going forward. We have also
adopted the Sustainability Accounting Standards Board (SASB)framework and are following its guidelines to disclose criticalmeasurements on environment, society and governance that arerelevant to our business.

2023

2022

2021

Unit

SASB Code

6%

7%

6%

Rate

HC-BP-330a.2

Involuntary turnover rate for professionals

3.1%

2.7%

1%

Rate

HC-BP-330a.2

Employee Engagement Score

83%

84%

84%

Discussion of talent recruitment andretention efforts for scientists and researchand development personnel

Employees are our most important resource, and we strive to attract andretain the most qualified people to fulfill our core purpose. Our goal is todevelop and retain value in our own products which could one day
transform cancer treatment. We believe that fostering workplace diversity
across social, educational, cultural, age and gender lines is aprerequisite for the continued success of the company. We arecommitted to diversity at all levels of the company and strive to recruit
employees with the right skills and competencies, regardless of gender,
age, ethnicity and otherdifferences. The ability to organize our highly
skilled and experienced team members at all levels of the organization
into interactive teams is a key factor in achieving our goals and ensuring
our success.

HC-BP-330a.1

How Employee Engagement Surveys areIntegrated Into HCM Strategy

In 2023, we conducted a global employee engagement survey on fivetopics: camaraderie and teamwork, career development, empowerment
and trust, performance management, and work-life balance. Team
members scored Genmab on 13 proven engagement drivers, which helps
us keep a pulse on areas of concern. We achieved an 83% engagementscore and an 88% global participation rate. Our results outpaced Life
Sciences industry benchmarks, which are typically 78% engagement scoreand 80% participation rate. Focus groups will be conducted in 2024 togenerate further insights on critical engagement issues.

Strategy and Programs Around Engagement,
Training and Development Benefits

We have a focused effort to continue building our learning culture,including curation and development of new virtual learning content
through our GenSpire platform, as well as initiating custom, targetedlearning programs. We revamped our leadership development programs
and aligned curriculum to mirror the Genmab Leadership Model, which
gives direction for our leaders’ behavior across the company fromprofessional to executive levels. 210 leaders enrolled in leadershipdevelopment programs, and over 500 people joined professional
development in-person trainings. We enhanced our foundational talentmanagement organization and team member development strategies andmobility within the organization. Our career framework that outlines career
pathways, levels, responsibilities and role-based competencies is helping
the organization scale in a disciplined manner. We continued to develop aformal succession planning process to ensure we are creating career
opportunities for our internal talent. We continued our competitive Total
Rewards strategy with long-term incentives in the form of share-basedcompensation. We continued our investment in a market competitive
benefits package and a pay-for-performance approach to rewards.

MetricHuman Capital Management
Employee Recruitment, Development & Retention
Voluntary turnover rateMetric

2023

2022

2021

Unit

SASB Code000

Number

HC-BP-210a.2

We have a company-wide quality policy to ensure that our products meetthe current regulations of the Danish Medicines Agency, the EuropeanMedicines Agency (EMA), the United States Food and DrugAdministration (FDA), Japan’s Pharmaceuticals and Medical Devices
Agency (PMDA), International Council for Harmonization (ICH) Quality
guidelines, Health Insurance Portability and Accountability Act (HIPAA),
and that they meet customers’ expectations.

HC-BP-210a.1

SocialSafety of Clinical Trial Participants
Number of FDA Sponsor Inspections related toclinical trial management and pharmacovigilancethat resulted in: (1) Voluntary Action Indicated (VAI)
and (2) Official Action Indicated (OAI)
Discussion, by world region, of management
process for ensuring quality and patient safety
during clinical trials

We have a strong quality culture that is led by senior leadership andlived every day by all our team members – making quality core toeverything we do.
Drug Safety
List of products listed in the Food and Drug
Administration’s (FDA) MedWatch Safety Alerts for
Human Medical Products database

21

None

n/aHC-BP-250a.1

Number of fatalities associated with products asreported in the FDA Adverse Event Reporting System

2930

NumberHC-BP-250a.2

Number of FDA enforcement actions taken
in response to violations of current Good
Manufacturing Practices (cGMP), by type000

NumberHC-BP-250a.5000

Number

HC-BP-260a.3

We use state-of-the-art technologies and processes in order to avoid
counterfeiting. This includes using various tamper evidences in ourproduct design, product tracking technologies and product ID test-points
throughout our supply chain. We work closely with local authorities ontackling counterfeiting, taking on board their recommendations.

HC-BP-260a.1

Counterfeit Drugs
Number of actions that led to raids, seizure,arrests, and/or filing of criminal charges related tocounterfeit products
Description of methods and technologies used tomaintain traceability of products throughout thesupply chain and prevent counterfeiting

Ethical Marketing
Total amount of monetary losses as a result of legal
proceedings associated with false marketing claims
Description of code of ethics governing promotion ofoff-label use of products

000

ReportingCurrency

HC-BP-270a.1

We do not promote any kind of off-label use, i.e. use for indications
which are not included in the product’s current Summary of ProductCharacteristics (SmPC)/product labeling. We do not encourageinquiries about off-label use nor provide any unsolicited information
on off-label use.

HC-BP-270a.2

We outsource the production, testing and distribution of products andthe conducting of clinical trials. Through vendor assessment andonboarding as well as operational and quality oversight, we ensure that
the Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs) and other service providers meet both our own
and applicable regulatory requirements, and that they meet industry
standards and best practices for quality and service, e.g., HACCP, ISO,ICH, etc.

HC-BP-430a.1

Supply Chain Management
Supply chain as it refers to Product Safety

Percentage of (1) entity’s facilities and (2) Tier I
suppliers’ facilities participating in the Rx-360
International Pharmaceutical Supply Chain
Consortium audit program or equivalent third-party
audit programs for integrity of supply chain andingredients0%n/an/aPercentage (%)

HC-BP-430a.1

Metric

2022

2021

2020

Unit

SASB Code000

ReportingCurrency

HC-BP-51 0a.1

GovernanceBusiness Ethics
Total amount of monetary losses as a result of legal
proceedings associated with corruption and bribery
Description of code of ethics governinginteractions with healthcare professionals

We have implemented several global compliance policies, guidelines
and procedures for key areas, including interacting with healthcare
professionals (HCPs), communicating and promoting products, andprohibiting acts of bribery and corruption.

HC-BP-51 0a.2

Governance
As a company operating in the global marketplace, we have policies andprocesses to reduce and manage the risks associated with bribery,corruption and other prohibited actions. Our Global Anti-Bribery andAnti-Corruption (ABAC) Policy ensures that team members understandthe definitions of bribery and corruption and how best to recognize
related risks, our zero-tolerance for prohibited actions, and themechanisms to report suspected or confirmed inappropriate activity. Allteam members receive annual training on ABAC. We are developing
additional due diligence, monitoring risk activities that enableenhanced oversight of business activities. We recently finalized a new
Quarterly Financial Disclosure Questionnaire that now incorporates
management disclosure of any potential bribery and/or corruption, thus
enhancing the Company’s risk and internal controls in this area.

n/aCorporate Governance - Key issues: Long-term Pay
Share-Based Compensation Awards incentivize executives to increase
Performance, CEO Equity Policy, Clawbacks & Malus, the long-term performance and success of Genmab and thereby support
Links Pay to Sustainability
sustainability.

n/aCorruption & Instability - Anti-bribery Policy

Incentive awards to executives are heavily dependent uponachievement of critical operating goals and our stock performance, andare primarily measured against objective metrics that we believe link
directly to the creation of sustainable value for our shareholders.
As described above, Genmab’s executive compensation program isprincipally designed to reward the Executive Management based on theachievement of performance objectives that, as a whole, are intended todrive sustainable long-term value creation for shareholders.

Environment
GHG emissions
We are committed to achieve a 42% reductionin Scope 1 and 2 GHG by 2030 compared toa 2021 baseline year. We are also committed
to reducing Scope 3 emissions by 2030
through supplier engagement and responsible
sourcing practices by having at least two-thirdsof our suppliers, by spend, covered by Paris
Agreement aligned climate targets.

GHG emissions
Total scope 1 e missions (tCO2e)
Total scope 2 emissions (tCO2e)

2023
317
238

Total scope 3* emissions (tCO2e)Electricity consumption (MWh)Share renewables

2021
341
298

147,721

Total scope 1,2 and 3 emissions (tCO2e)Electricity Consumption and Renewables

2022
283
111
147,327

2022
3,293

2021
3,127

2021
2,925

76.8%

94.0%

83.0%

* Our defined 2023 Scope 3 emissions is not yet available.

Metric2022

2021

2020

Unit

Environment (continued)
Toxic Emissions and Waste
Minimizing laboratory waste is a key priority of our Global
Sustainability Working Group. The management of laboratory waste at
Genmab is audited annually and the waste license is maintained incompliance with all rules and regulations. We carry out a yearly reviewof the use of highly toxic chemicals, and team members working in ourlaboratories are instructed to replace highly toxic chemicals with lesstoxic versions where feasible. Our U.S. laboratory continued its
regulated medical waste (RMW) recycling program – recycling 4,745 lbs.
(2,152 kgs.) of waste into plastic lumber. This type of waste contains asignificant amount of plastic, which would otherwise have to beincinerated.

Key Policies
Code of Conduct

https://ir.genmab.com/static-files/36f5805e-95d3-4bf8-9ae0-d09e7465edee

CSR Policy

https://ir.genmab.com/static-files/9ae42eae-7510-4d99-ace9-6af56de1 281c

Diversity, Equity and Inclusion Policy

https://www.genmab.com/our-responsibility#policies

Remuneration Policy

https://ir.genmab.com/static-files/10c7f9d1-abd8-448e-a6e3-8924305755a3

Speak-Up Policy

https://ir.genmab.com/static-files/25cf962a-e494-4c4f-9fc0-a9f84b151d07

Tax Policy

https://ir.genmab.com/static-files/7917403b-a5af-454e-a595-1006ae038562

Board Committee and Charters

https://ir.genmab.com/corporate-governance/board-committees-and-charters#content

Corporate Governance Report 2023

https://ir.genmab.com/corporate-governance#content

Compensation Report 2023

https://ir.genmab.com/governance/compensation#content

Commitment to Quality

https://www.genmab.com/our-responsibility#policies

Human Rights Commitment

https://ir.genmab.com/static-files/7e7f7a44-64bb-4a24-904e-ceec494de771

Global Supplier Code of Conduct

https://ir.genmab.com/static-files/da89c83f-529a-4404-8edb-dda71 a31 bc39

Data Ethics Policy

https://ir.genmab.com/static-files/f4659dac-a24c-4858-857b-ba70f70e518e

SASB Code